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ABSTRACT
Introduction Polycystic ovary syndrome (PCOS) is a 
common endocrine disorder in women of reproductive 
age and the leading cause of anovulatory infertility. 
Women with PCOS have a 15- fold higher prevalence 
of infertility, compared with women without PCOS, 
independent of body mass index (BMI). A healthy 
lifestyle is recommended to improve overall health and 
fertility in PCOS but there is limited evidence on the 
isolated effects of exercise, especially for reproductive 
outcomes. Previous findings indicate superior metabolic 
health benefits after vigorous compared with moderate- 
intensity exercise. Our primary aim is to determine 
the effect of high- intensity interval training (HIT) on 
menstrual frequency, as a proxy of reproductive function, 
in women with PCOS.
Methods and analysis The study is a two- centre, 
randomised, controlled trial with three parallel 
groups. Women (n=64) from Trondheim (Norway) and 
Melbourne (Australia) with PCOS according to the 
Rotterdam criteria will be randomly allocated (1:1:1) 
to high- volume HIT, low- volume HIT or a control group 
with no exercise after stratifying for BMI < or ≥ 27 kg/
m2 and study centre. Measurements for study end 
points will be undertaken at baseline, after a 16 week 
exercise intervention and at 12 months following 
baseline assessments. The primary outcome measure 
is menstruation frequency, measured as the number 
of self- reported menstrual bleedings divided by the 
number of expected menstrual bleedings during a 
12- month period. Secondary outcome measurements 
include markers of cardiovascular, metabolic and 
reproductive health, as well as quality of life and 
adherence to and enjoyment of exercise.
Ethics and dissemination The Regional Committee 
Medical Research Ethics, Norway, and The Australian 
Catholic University Human Research Ethics Committee, 
Australia, have approved the trial protocol. This trial will 
provide new insight regarding the impact of exercise on 
fertility in PCOS. We expect this trial to contribute to new 
therapeutic exercise strategies as part of clinical care 
for women with PCOS.
Trial registration number Clinical trial gov 
NCT02419482.
InTRoduCTIon
Polycystic ovary syndrome (PCOS) is a 
complex endocrine disorder1 2 affecting 
8%–13% of reproductive- aged women.3 
The ovulatory disturbance is a central diag-
nostic feature of PCOS,4 and the syndrome 
is recognised as the leading cause of anovu-
latory infertility and menstrual disorders.5 
A large community- based cohort study 
reported a 72% prevalence of infertility 
among women with PCOS, compared 
with 16% among women without PCOS.6 
Strengths and limitations of this study
 ► This will be the first randomised controlled trial to 
determine the isolated effects of two different high- 
intensity interval training protocols on reproductive 
and health- related outcomes in women with poly-
cystic ovary syndrome, with a follow- up time of 12 
months.
 ► The exercise intervention is controlled and mon-
itored through partly supervised sessions for 16 
weeks.
 ► We will include women within all body mass index 
categories.
 ► Investigators will not be blinded for all assessments 
due to the difficulty blinding investigators and par-
ticipants to a behavioural intervention.
 ► Menstrual frequency is only a proxy for reproduc-
tive function, and we will not undertake ovulation 
monitoring.
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According to the most recent guidelines for the assess-
ment and management of PCOS, lifestyle intervention 
is regarded as first- line therapy to manage reproductive 
and metabolic outcomes.4 In addition to reproduc-
tive dysfunctions, PCOS is associated with a number 
of adverse cardiovascular, metabolic and psycholog-
ical outcomes across all categories of body mass index 
(BMI).2 4 7–9 Obesity seems to exacerbate the clinical 
features in PCOS, but also weight- independent insulin 
resistance is strongly implicated in the aetiology of 
PCOS, contributing to the reproductive and meta-
bolic complications.10–13 Approximately 40% of women 
with PCOS have a normal BMI (<25 kg/m2) and the 
prevalence of insulin resistance among lean women 
with PCOS is estimated to be around 75%.14 Adipose 
tissue dysfunction, such as hypertrophic adipocytes 
and impairments in lipolysis and insulin action, plays a 
central role in the metabolic abnormalities observed in 
PCOS.15 Hypertrophic adipocytes are more susceptible 
to inflammation and chronic low- grade inflammation 
in PCOS.16 There is limited research on the effect of 
exercise training on adipose tissue function and low- 
grade inflammation in PCOS.
Exercise training positively affects metabolic, cardio-
vascular and psychological outcomes in women with 
PCOS, but the effect on fertility is unclear.4 12 17–19 Some 
trials20–24 and systematic reviews12 25 report improved 
ovulation or menstruation frequency after a period 
of exercise training or after a combined exercise- diet 
intervention.26 Two of these studies indicate a weight- 
independent effect of exercise on fertility, suggesting 
insulin sensitivity to be a key factor.21 23 Only one study to 
date has investigated the effect of exercise on menstru-
ation frequency in women with PCOS having normal 
or low BMI (<25 kg/m2).22 In that study, they found a 
significant improvement in menstruation frequency 
(from 48 to 27 days) after 8 weeks (three sessions per 
week) of aerobic and resistance training. However, 
8 weeks follow- up may be too short to determine any 
effect of exercise training on menstrual frequency. 
Furthermore, inconsistent reporting of fertility- related 
outcomes, small sample sizes and short intervention 
periods, make it difficult to interpret the effect of exer-
cise on fertility.2 4 12 25
Despite growing evidence on health benefits of 
exercise training in PCOS,4 12 27 there is a lack of well- 
designed randomised controlled trials of different exer-
cise protocols including long intervention and follow- up 
periods to determine the isolated effect of exercise on 
fertility outcomes
. Most studies to date have only included overweight/
obese participants and less is known about the potential 
benefits in women with PCOS who have BMI ≤25 kg/m2. 
Although moderate- intensity exercise provides health 
benefits, only vigorous, and not moderate- intensity, 
physical activity was associated with reduced odds of 
insulin resistance and metabolic syndrome in a cross- 
sectional study of women with PCOS.18 Indeed, there 
is an increased focus on high- intensity interval training 
(HIT) as a means of improving insulin sensitivity28 and 
cardiorespiratory fitness29–31 in clinical populations, 
including PCOS.32 HIT involves brief, repeated work 
bouts of relatively intense exercise separated by periods 
of rest or low- intensity exercise. Several different HIT 
protocols exist, and they can broadly be divided into 
‘high- volume’ (HV) and ‘low- volume’ (LV) HIT. One 
of the most common HV- HIT protocols is the Norwe-
gian 4×4 min HIT protocol, which induces superior 
improvements in cardiorespiratory fitness compared 
to work- matched moderate- intensity training in both 
healthy individuals33 and in various patient groups.29 34 
LV- HIT typically consists of ≤10 min of intense exercise 
within an exercise session lasting ≤30 min in total, such 
that the total weekly training time commitment is mark-
edly lower than the current public health guidelines.35 
LV- HIT could therefore have the potential to overcome 
the most common barriers for women in fertile age, such 
as time commitment.36 LV- HIT can improve glycaemic 
control in people with type 2 diabetes.37 We have previ-
ously reported improved insulin sensitivity (measured 
with homeostatic assessment of insulin resistance, 
HOMA- IR), endothelial function and body composition 
after 10 weeks of HIT in women with PCOS, without any 
changes in body mass.32 However, in that pilot study, the 
participants undertook both LV- HIT and HV- HIT and 
we did not determine the effects of exercise training 
on any reproductive outcomes. Based on the positive 
results from our pilot study with a combined HV- HIT 
and LV- HIT protocol, we will now compare the two 
different HIT protocols to investigate potential differ-
ences in health outcomes.
Here we describe the design, methodology and poten-
tial clinical significance of the ‘IMproving Reproductive 
function in women with Polycystic OVary syndrome by 
high- intensity Interval Training (IMPROV- IT) trial’.
AIMS
The primary aim of the IMPROV- IT trial is to test 
the hypothesis that 16 weeks of semi- supervised HIT, 
followed by home- based HIT for 36 weeks, will increase 
menstruation frequency, as a proxy measure of ovula-
tion, during 1 year of follow- up in women with PCOS, 
compared with a non- exercising control group.
Secondary aims are to determine if there are 
improvements in: ovarian morphology, insulin sensi-
tivity, endothelial function, intima- media thickness, 
body composition, cardiorespiratory fitness, oxidative 
capacity, circulation markers of reproductive and meta-
bolic health, low- grade systematic inflammation (in 
blood and adipose tissue), adipose tissue morphology 
and function, and quality of life, after 16 weeks of semi- 
supervised HIT, as well as after the following 36 weeks 
of home- based HIT.
Additionally, we will record the adherence to exercise 
training and enjoyment of two different HIT protocols 
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Figure 1 Consort flow diagram. BMI, body mass index; HV- 
HIT, high- volume high- intensity interval training; LV- HIT, low- 
volume high- intensity interval training.
and assess if the two protocols induce different effects 
on the aforementioned measures.
METhodS And AnAlySIS
Study setting and recruitment
This is a two- centre, randomised controlled trial with three 
parallel groups; two training intervention groups and 
one control group. The two study centres are the Norwe-
gian University of Science and Technology (NTNU) in 
Trondheim, Norway and the Australian Catholic Univer-
sity (ACU) in Melbourne, Australia. Testing and training 
will take place in the university research laboratories in 
both Norway and Australia. Participants will be recruited 
from the public announcement at hospitals and univer-
sity homepages, at local stores, public places and social 
media. All participants will sign a written, informed 
consent. All participants will have a project- specific code 
that will be used during all analyses of the data. The 
procedures for data entry, coding and storage have been 
approved by the Regional Committee Medical Research 
Ethics in Mid- Norway.
Participants
To be eligible for inclusion in the study, women will have 
to meet the following criteria:
 ► Aged 18–45 years old.
 ► PCOS diagnosis according to the Rotterdam criteria,38 
as confirmed by a gynaecologist, endocrinologist or 
general practitioner. Thus, a minimum of two of the 
following criteria have to be present: (1) polycystic 
ovary morphology (12 or more 2–9 mm follicles or 
>10 mL in volume, in at least one ovary), (2) hyper-
androgenism (either clinical signs as hirsutism or 
acne, or biochemical), and (3) oligo/amenorrhoea. 
Oligomenorrhoea is defined as an intermenstrual 
interval >35 days and/or ≤9 menstrual bleeding in 
the past year. Amenorrhoea is defined as no vaginal 
bleeding the last 3 months for women with a previ-
ously regular menstrual cycle; no vaginal bleeding the 
last 12 months for women with an irregular menstrual 
cycle.39 40 Hirsutism will be defined as modified 
Ferriman Gallwey score41 ≥8.4
 ► At the Norwegian centre, all participants will be 
screened at baseline for polycystic ovaries, hyperan-
drogenism and menstruation frequency to confirm 
the PCOS diagnosis. At the Australian centre, partic-
ipants will show an ultrasound scan no older than 8 
years performed by their general practitioner, gynae-
cologist or endocrinologist confirming polycystic 
ovaries. Ferriman Gallway score for hirsutism/hyper-
androgenism and information about their menstrual 
cycle will be obtained before entering the study to 
confirm PCOS diagnosis.
 ► Undertaking less than 2 weekly endurance exercise 
training sessions with an intensity that induce heavy 
breathing.
Women will be excluded from the study if they meet 
any of the following criteria:
 ► Current treatments with hormonal contraceptives 
including Mirena intrauterine device.
 ► Insulin sensitisers or drugs known to affect gonado-
tropin or ovulation (with a washout period of 3 months 
prior to inclusion).
 ► On- going pregnancy or breastfeeding within 24 weeks.
 ► Cardiovascular disease or other endocrine disor-
ders (eg, congenital adrenal hyperplasia, Cushing 
syndrome or androgen- secreting tumours).
Randomisation and allocation
Participants will be allocated 1:1:1 to HV- HIT, LV- HIT, or 
control after stratifying for BMI <or ≥ 27 kg/m2 and study 
centre (figure 1). A computer random number gener-
ator developed and administered at the Faculty of Medi-
cine, Department of Public Health and General Practice, 
NTNU, Trondheim, Norway, will be used at both study 
centres. The investigators will be informed about the 
allocation results by e- mail after the registration of new 
participants.
Interventions
The first 16 weeks of the exercise training will be semi- 
supervised, with the remaining 36 weeks of the interven-
tion organised as home- based exercise training without 
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Figure 2 HIT protocol. Panel A: low- volume hit; Panel B: 
high- volume hit. HIT, high- intensity interval training.
any supervision. Supervised exercise interventions are 
effective, but do not resemble a real- life setting, and the 
long- term adherence often falls once the supervised exer-
cise programme ends. Unsupervised exercise programme 
are more easily implemented and flexible, but adherence 
is often low. During the first 16 weeks, the participants 
will perform at least 1 weekly supervised exercise session 
at the study centres. They will be given the opportunity 
to attend up to 3 weekly supervised exercise sessions but 
can also choose to do one or two of the weekly sessions as 
home- based training. The participants will be encouraged 
to continue to complete at least 2 weekly sessions (home- 
based and unsupervised) for the remaining 36 weeks of 
the study period. Participants receive a heart rate monitor 
that they will wear on all sessions and will be required 
to register all their exercise sessions during the whole 
study period through an online exercise- training diary 
( www. polar. flow. com). The researchers will have access 
to all sessions via the same online tool and will supervise 
exercise adherence at the home- based sessions; however, 
no motivational support or instructions will be provided 
during the follow- up period. We will be advising women 
in the control group to continue their habitual physical 
activity and inform them about the current recommen-
dations of a minimum of 150 min of weekly moderate- 
intensity physical activity.
HIT protocols
The LV- HIT protocol consists of a 10 min warm- up at light 
to moderate intensity at 60%–70% of HRmax followed by 
ten 1 min work bouts at the maximal intensity the partic-
ipants can complete for 1 min. In the initial training 
session, the intensity will be set corresponding to 100% 
of the workload the participant reached at the baseline 
VO2max test. Participants will be instructed to try reaching 
90% of maximal heart rate (HRmax) during the third or 
fourth work bout, based on previous findings from Little 
et al.37 The work bouts are separated by 1 min of passive or 
low- intensity recovery, trying to reach 60%–70% of HRmax. 
The training session is terminated after a 3 min cool- down 
at 60%–70% of HRmax. The total exercise time is 32 min 
(figure 2A).
The HV- HIT protocol consists of a 10 min warm- up at 
60%–70% of HRmax, followed by four 4 min work bouts 
reaching 90%–95% of HRmax, separated by a 3 min active 
recovery of running/walking at 60%–70% of HRmax. The 
training session is terminated after a 3 min cool- down 
at 60%–70% of HRmax. The total exercise time is 38 min 
(figure 2B).
The LV- HIT and HV- HIT are not matched for time, 
mean workload and energy expenditure. HIT will be 
performed as treadmill walking or running. Heart rate 
monitors (Polar M400) will be used on all sessions, 
including on the home- based sessions, and the exercise 
intensity will be estimated based on their HRmax during 
the VO2max test at baseline.
42 Where required (due to 
injury, pain or discomfort), the participants will be able 
to exercise on other ergometers (bikes or elliptical 
machines). Participants can also choose to perform some 
of the sessions as outdoor running/uphill walking. We 
will adjust the absolute workload of both LV- HIT and 
HV- HIT throughout the intervention period to account 
for improvements in fitness.
outcome measures
Outcomes will be assessed at baseline, at 16 weeks (post 
intervention) and at 12 months from baseline (follow- up) 
in Trondheim, Norway. In Melbourne, Australia, measure-
ments will be assessed at baseline and after 16 weeks, and 
only questionnaires and menstrual frequency will be 
assessed until 12 months from baseline. Participants will 
be asked not to exercise for >48 hours prior to the test 
visits in the laboratory and to abstain from caffeine intake 
for 24 hours prior to the tests. Measurements will be 
undertaken during the follicular phase of the menstrual 
cycle (1–7 days after first bleeding) in women with a 
regular menstrual cycle.
Menstrual frequency
The primary outcome measure is menstrual frequency. 
Participants will register the first day of their menstrual 
cycle and length (number of days) during the 12- month 
study period. They will send their menstruation dairy to 
the study personnel after each menstrual cycle, and the 
study personnel will send out reminders to fill out the 
diary. In addition, participants will complete a question-
naire about their menstrual cycle at each assessment point 
(baseline, 16 weeks and 12 months). We will compare 
the number of menstrual bleedings between the groups, 
measured as the number of observed menstrual bleed-
ings divided by the number of expected menstrual bleed-
ings (n=13, assuming a cycle interval of 28 days) during 
a 12- month period. The menstrual frequency is to be 
measured as a proxy for ovulation. Menstrual frequency 
assessments will be undertaken non- blinded for the study 
personnel.
Ovarian morphology
Ovarian morphology will only be assessed at the site in 
Norway. The ultrasound assessments of the ovaries include 
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ovarian volume in mL (with and without a dominating 
follicle), dominating follicle volume in mL, number of 
follicles in each ovary, diameter and distribution of folli-
cles. We will use a multifrequency transvaginal transducer 
on all measurements. An experienced gynaecologist 
(MAHR) will perform all imaging and measurements. 
Ovarian morphology assessments will be undertaken 
blinded for group allocation.
Fertility and pregnancies
Background information regarding fertility will be regis-
tered by questionnaires. These include questions about 
number of children, natural or assisted fertilisation, if 
the participants are actively seeking pregnancy or have 
tried to become pregnant, for how long they have tried to 
become pregnant, and if they have experienced miscar-
riages or had abortions. We will report the number of 
pregnancies during the intervention period, including 
during the 12 months of follow- up. Questionnaires will be 
undertaken blinded, whereas the number of pregnancies 
will be undertaken non- blinded for the study personnel.
Blood biochemistry and insulin sensitivity
Blood samples will be obtained after an overnight fast 
(no food or fluid intake except water 12 hours prior to 
assessments) at each time point. Analysis of fasting venous 
blood samples will include measurements of 17- OH 
progesterone (baseline only), prolactin (baseline only), 
haemoglobin, glycated haemoglobin, blood lipids (total 
cholesterol, high- density lipoprotein cholesterol, low- 
density lipoprotein cholesterol and triglycerides), blood 
glucose, white blood cell count (neutrophils, basophils, 
eosinophils, lymphocytes and monocytes) and leucocytes. 
Additional blood (including buffy coat) will be stored 
for later analyses. These later analyses will likely include, 
but are not limited to, androstenedione, anti- Müllerian 
hormone, sex hormone- binding globulin, testosterone, 
insulin, leptin, adiponectin and micro- RNAs. We will also 
obtain two Tempus RNA tubes from each participant for 
later assessments of gene expression.
After fasting blood samples, glycaemic control will 
be measured using a 2- hour oral glucose tolerance test 
(OGTT). The participants will consume 75 g of glucose 
diluted in 250 mL water. Blood will be sampled for insulin 
and glucose measurements at 0 (prior to the OGGT), 30, 
60, 90 and 120 min from an indwelling catheter. Glycaemic 
control will be calculated as total area under the curve 
(AUC) and incremental area under the curve (iAUC; 
using fasting concentrations as baseline values) using the 
trapezoid method, for glucose and insulin concentra-
tions, and peak concentrations during the OGTT. Insulin 
sensitivity will be estimated using the HOMA- IR; fasting 
serum insulin in μU/mL × fasting plasma glucose in 
mmol/L/22.5.43
Biological materials collected at NTNU will be stored 
in the Regional Research Biobank at St Olav’s Hospital 
(Biobank1, https:// biobank1. no/ nb/). Biological mate-
rials from collected at ACU will be stored locally until 
data collection is completed in Australia, and later sent to 
Norway. Sample collection and handling are performed 
in accordance with hospital/laboratory standard proce-
dures. Blood sampling and OGTT will be undertaken 
blinded in Norway and unblinded in Australia.
Cardiorespiratory fitness and substrate utilisation
Peak oxygen uptake will be measured on a treadmill, using 
indirect calorimetry (Oxycon Pro, Jaeger, Germany in 
Norway/TrueOneRMR, Parvo Medics, USA in Australia). 
Participants will walk or run until voluntary exhaustion 
using an individualised protocol. After a 10 min walking 
warm- up, the test will start by walking at moderate intensity 
for 3 min. The speed or inclination will then be increased 
every 1–2 min, by 0.5–1.0 km/h or 1%–2%. The cardiore-
spiratory fitness test will be considered successful with a 
plateau in VO2 with a further increase in workload, and a 
respiratory exchange ratio ≥1.05. Peak oxygen uptake will 
be calculated as the highest consecutive 30 s measured, 
both absolute (mL/min) and relative (mL/min/kg). The 
maximal heart rate obtained during the exercise test at 
baseline will serve as the basis for calculating the intensity 
during the HIT sessions.
After an overnight fast (no food or fluid intake except 
water 12 hours prior to assessments), participants will 
complete a submaximal test on a treadmill. The protocol 
includes a 20 min warm- up, followed by 20 min steady- 
state expired gas sampling at 60% of peak oxygen uptake. 
We will ask participants to record their diet the day before 
the baseline test of oxidative capacity and to repeat this 
diet before the subsequent measures (at 16 weeks and 12 
months). Fat oxidation rates (g/min) will be calculated 
from 5 min of stable oxygen uptake at the final stage 
of the test (during the last 10 min), using the following 
equation: 1.695 × VO2 – 1.701 × VCO2,
44 where VO2 is 
oxygen uptake and VCO2 is the volume of expired carbon 
dioxide. Assessments of these outcomes will be under-
taken non- blinded for the study personnel.
Adipose tissue composition, morphology and function
Abdominal and gluteal subcutaneous adipose tissue biop-
sies (~300–500 mg) will be collected under local anaes-
thesia (1% xylocaine) using a 14- G sterile needle. For a 
subsample of participants, ~80 mg of each biopsy will be 
allocated for immediate analyses of mitochondrial respi-
ration using high- resolution respirometry (Oxygraph- 2K, 
Oroboros, Austria). Approximately 200–300 mg will be 
snap- frozen in liquid nitrogen and stored at −80°C for 
later analyses, such as micro RNAs, gene expression and 
protein profiling. The remaining tissue will be immedi-
ately fixed in phosphate- buffered formalin, processed 
and embedded in paraffin and sectioned at 4 μm for 
morphology and inflammation analyses. The sections 
will be incubated with CD45 and CD68 antibodies to 
detect leucocytes and macrophages. These sections will 
be captured with an EVOS FL Auto 2 Imaging System 
(ThermoFisher Scientific, USA) and analysed with the 
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open- source software ImageJ (Fiji).45 Assessments of 
these outcomes will be undertaken blinded.
Physical activity and diet
We will monitor physical activity by questionnaires and 
5- day activity monitoring (Sensewear Armband, APC 
Cardiovascular, UK) and record diet through a 4- day diet 
recall, at each measurement point. Assessments of phys-
ical activity and diet will be undertaken blinded.
Quality of life
Quality of life will be assessed using the Polycystic Ovary 
Syndrome Questionnaire.46 Assessment of this outcome 
will be undertaken blinded.
Anthropometrics and body composition
Anthropometric measurements will be conducted when 
participants are fasted (no food or fluid intake except 
water 12 hours prior to assessments). Height will be 
measured standing, without shoes using a standard stadi-
ometer. Total body mass and body composition will be 
measured wearing light clothing with no metal items and 
without shoes or socks using bioelectrical impedance 
analysis (InBody720 bioimpedance scale, Biospace CO, 
Korea) in Norway and dual- energy X- ray absorptiom-
etry (DXA; GE Lunar iDXA Pro, encore software version 
16, General Electric, Boston, Massachusetts, USA) in 
Australia. For the DXA scan, participants are required to 
lay supine on the scanning bed for the duration of the 
scan, which is approximately 15 min with one or two scans 
depending on the body shape of the participant. Waist 
and hip circumference will be measured to the nearest 
0.5 cm horizontally at the level of the umbilicus, while 
standing and at normal expiration, using a metric tape. 
Assessments of these outcomes will be undertaken non- 
blinded for the study personnel.
Blood pressure and resting heart rate
Blood pressure and resting heart rate will be measured 
in the seated position after 15 min rest with an auto-
matic blood pressure device three times on the left arm 
(diastolic and systolic, in mm Hg). The mean of the three 
measurements will be used to calculate blood pressure 
and resting heart rate. Assessments of these outcomes 
will be undertaken blinded in Norway and unblinded in 
Australia.
Endothelial function and intima-media thickness
Endothelial function and intima- media thickness (IMT) 
will be assessed at the Norwegian site only. Following a 
20 min supine rest period, the diameter of the brachial 
artery will be imaged (12 MHz Doppler probe, GE 
Vingmed Ultrasound AS, Horten, Norway). A cuff will 
be placed around the forearm (immediately distal to 
the olecranon) to produce the stimulus of forearm isch-
aemia. When an optimal image is obtained, the probe 
will be held stable and the ultrasound parameters will 
be set to optimise the longitudinal, B- mode image of 
the lumen–arterial wall interface. The ultrasound will 
also be used to attain simultaneous continuous Doppler 
velocity using the lowest possible insonation angle (60°). 
A recording of resting diameter and velocity will be taken 
for 1 min, then the forearm cuff will be inflated (>200 mm 
Hg) for 5 min. Both diameter and velocity recordings will 
resume 30 s before cuff deflation and continue for 3 min 
after deflation.47 This flow- mediated dilation (FMD) 
test is a measure of endothelial function. We will also 
measure carotid artery IMT in three angles: transversal, 
longitudinal and anterolateral using ultrasound (12 MHz 
Doppler probe, GE Vingmed Ultrasound AS, Horten, 
Norway). Measurements of the diameter will be imaged 
1 cm below the bifurcation on the right side. Images will 
be obtained where the near wall is clearly visualised, with 
a double- line pattern and at the minimal diameter during 
the cardiac cycle as previously described elsewhere.48 The 
same person (IAK) will perform all the FMD and IMT 
measurements. Assessments of these outcomes will be 
undertaken non- blinded for the study personnel.
Enjoyment
A subgroup of participants (the last 40 to be included 
in the trial) allocated to one of the training groups will 
complete a Physical Activity Enjoyment Scale (PACES)49 
as well as The Borg’s scale50 to assess enjoyment and 
perceived exertion at one supervised weekly training 
session. Assessments of these outcomes will be under-
taken non- blinded for the study personnel.
Sample size and statistical analysis
We computed the sample size for a one- way analysis of 
variance test with three groups. In women with PCOS, 
a menstrual frequency of on average 4.5 menstrual 
bleeding during 1 year is expected.51 With a statistical 
power of 80%, a significance level of 0.05 and a SD of 
two menstrual bleeding during a 12- month period, we 
calculated that 48 women will be required to detect an 
increase in menstrual bleeding to 7.5 in the intervention 
groups.26 Because of the non- normality of menstrual 
frequency, it may be necessary to use a non- parametric 
test. Non- parametric tests require more participants and 
we, therefore, added 15% to the required sample size. 
Additionally, to allow for expected dropouts of 10%–15%, 
we aim to include 64 women in the study.
We will perform all the statistical analyses blinded for 
group allocation. The primary analysis will be a compar-
ison between groups for the number of menstrual 
bleeding during 12 months. We will adjust for the self- 
reported menstrual frequency at baseline. We will include 
all women who have reported menstrual frequency in the 
primary analysis, independent of adherence to the inter-
ventions, that is, intention- to- treat analysis. The number 
of pregnancies during the 16 weeks of intervention and 
during the 12- month follow- up will be compared between 
groups. Secondary outcome measures will be compared 
between groups after 16 weeks and after 12 months and 
adjusted for baseline values. We will do additional ‘per 
protocol’ analyses where we include women in the HIT 
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groups that have completed >75% of the scheduled exer-
cise sessions during the intervention period (for compar-
isons after 16 weeks) and a mean minimum of one HIT 
session/week during the 12- month follow- up (for compar-
isons at the end of follow- up).
Results will be reported as means with 95% CIs and/or 
SD. We will report the effect of HIT as mean changes from 
baseline to 16 weeks of intervention and after 12 months 
of follow- up. We will use mixed models to test differences 
between groups. P values <0.05 will be considered signif-
icant for both primary and secondary outcomes. We will 
also perform subgroup analyses to investigate differences 
between BMI categories and compare adherence rates 
and enjoyment of the two HIT protocols.
Blinding
We are unable to blind group allocation to participants 
or study personnel due to the nature of the intervention 
(supervised exercise training). All baseline assessments 
will be undertaken prior to randomisation and some 
assessments will be undertaken blinded for group alloca-
tion (as outlined for each outcome measure).
Monitoring
The investigators are responsible for the documentation 
of any adverse event or serious adverse event. Participants 
will be told to contact the investigator if they have any 
unusual symptoms. We will record all medical events 
during the study in the Case Report Form. In addition, we 
record serious adverse events in a Serious Adverse Events 
Report Form. All serious adverse events will be reported 
to the sponsor within 24 hours after the site has gained 
knowledge of the event.
Patient and public involvement
No patients were involved in the development of the 
research question or design of the study. All partici-
pants will be invited to a 1- hour educational session 
about healthy diet and physical activity. We will also give 
general information about PCOS in these meetings and 
encourage the participants to ask questions and give us 
feedback about relevant topics or issues related to their 
disorder and to the trial implementation. Individual 
test results will be disseminated to each participant after 
testing. We will also send out a summary of the study 
results to all participants at the completion of the study.
EThICS And dISSEMInATIon
The study is approved by the Regional Committee 
Medical Research Ethics in Mid- Norway and The ACU 
Human Research Ethics Committee and has its origin in 
the Declaration of Helsinki and is consistent with ICH/
Good Clinical Practice and applicable regulatory require-
ments. All protocol modification must be approved by 
the Regional Committee Medical Research Ethics in 
Mid- Norway and by The ACU Human Research Ethics 
Committee.
We will publish the results from the study as peer- 
reviewed articles in international journals. Our results will 
also be communicated through the Norwegian society 
of infertility, through social media channels as well as at 
national and international conferences.
dISCuSSIon
Infertility and risk of lifestyle- related diseases (obesity, 
metabolic, cardiovascular and psychological diseases) are 
the main health challenges associated with PCOS, both for 
the individuals affected by the syndrome, the healthcare 
systems and society.2 4 To date, no treatment fully reverses 
or cures the symptoms of PCOS40 and lifestyle interven-
tions are recommended as first- line therapy according 
to recent guidelines.4 52 Nevertheless, there is limited 
research available to give women with PCOS sufficient 
recommendations on physical activity and exercise. Some 
studies have demonstrated positive effects in reproductive 
outcomes after exercise, with concomitant improvements 
in insulin sensitivity and/or visceral fat.20–24 However, 
more knowledge is needed about the underlying mecha-
nisms for improvement in fertility after exercise training, 
as discussed in several systematic reviews on lifestyle inter-
ventions and fertility.12 25 53 54 HIT has shown to be time 
efficient, safe and well tolerated, with positive effects 
on metabolic and cardiovascular risk factors in several 
studies.29 55 56 Larger studies investigating the adherence 
to HIT are lacking among women in general, and among 
women with PCOS in particular. This is of great interest, 
as we need to find exercise and lifestyle programmes that 
are feasible over time and that can be easily implemented 
in everyday life. Exercise programmes that are efficient 
in a research setting are not necessarily effective in a real- 
life setting. Thus, there is a great need for studies with a 
longer intervention and follow- up period.
Our trial has some limitations. The use of menstrual 
frequency as a proxy for ovulation/reproductive function 
is one of these. Due to practical reasons, we are not able 
to undertake ovulation monitoring. The Inbody 720 and 
DXA are both reliable methods to measure fat- free mass 
(FFM), body fat percentage (BF%) and fat mass (FM) but 
it has been shown that the InBody 720 overestimates FFM 
and underestimates BF% and FM compared with DXA .57 
For each individual participant, the same measurement 
method will be used (InBody 720 in Norway and DXA in 
Australia) and our purpose is to evaluate changes in body 
composition (ie, delta changes). Assessing enjoyment 
of exercise only at the supervised sessions could imply 
a bias. On the supervised sessions, the participants will 
receive motivational support from the researchers and 
potentially also social support from other participants 
that can affect their ratings of enjoyment. The enjoy-
ment ratings are, however, implemented to compare 
the perceived enjoyment of the two HIT protocols. The 
semi- supervised nature of the trial could imply that some 
participants choose to undertake all sessions supervised, 
whereas others choose to exercise at home for most 
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sessions. We chose to implement a semi- supervised exer-
cise programme to account for the individual preferences 
of the participants and to be able to include women living 
further away from the study centres. Such protocols can 
both control the exercise intervention and motivate 
participants, and at the same time give more flexibility 
based on participants’ preferences.
The IMPROV- IT trial will determine the effect of 
HIT on reproductive, cardiovascular, metabolic and 
psychological health in women with PCOS. The trial will 
contribute evidence of more specific exercise protocols 
in the treatment and management of PCOS for clinicians 
and answer some of the current limitations addressed 
by both the International evidence- based guidelines for 
the assessment and management of PCOS4 and several 
systematic reviews.2 12 25 58 This trial is highly relevant and 
important as PCOS is a major burden for the women with 
PCOS, the health services and society. As for now, we do 
not have an optimal treatment.
Trial status
We have recruited 64 women with PCOS to the IMPROV- IT 
study, with the last included participant in March 2019. 
The last follow- up will be in March 2020.
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